



Marksans Pharma Ltd.

Date: 17th June, 2021

**National Stock Exchange of India
Limited**

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Clarification

Dear Sir,

This is with reference to the Exchange's e-mail communication dated 17th June, 2021 regarding amendment to Articles of Association of the Company. In this connection, we would like to state as under.

In connection with an offer of OrbiMed Asia IV Mauritius FVCI Limited ("OrbiMed") to the Company to participate in the issue of convertible warrants on preferential basis, OrbiMed and the Company will enter into a Warrant Subscription Agreement approved by the Board of Directors in its meeting held on 15th June, 2021. One of the condition of the said offer is that the Articles of Association of the Company be amended to include the provisions of the Warrant Subscription Agreement.

In view thereof, the current set of Articles of Association of the Company need to be amended and restated to incorporate the provisions of the above Warrant Subscription Agreement.

Hope we have clarified the position.

Thanking You,

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com